KRAS and exocrine pancreatic carcinoma: Considering the 458,918 new cases of pancreatic carcinoma reported in 2018 (91) and that ⁓5 to 10% of these lack KRAS alterations, we estimate that several thousand patients of this disease group alone will be potentially diagnosed with druggable BRAFΔβ3-αC mutants annually.